重症监护后使用抗抑郁药物:一项全国性的队列研究
Erik von Oelreich1,2, Jesper Eriksson3,4, Mikael Eriksson5,6
1Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, 171 76, Stockholm, Sweden. erik.von.oelreich@ki.se.
Scientific reports
|July 9, 2024
概括
许多重症监护室 (ICU) 幸存者开始服用抗抑郁药物,使用量随着时间的推移而增加. 这项研究发现,抗抑郁药的使用与这些患者的较高死亡率有关.
科学领域:
- 临界护理医学 临界护理医学
- 精神病学是一个精神病学.
- 公共卫生 公共卫生
背景情况:
- 重症监护室 (ICU) 的生存率有所改善,但许多幸存者经历了长期的心理健康问题,如抑郁和焦虑.
- 这些后ICU条件会对生活质量产生负面影响,并可能增加死亡风险.
研究的目的:
- 为了确定ICU幸存者的抗抑郁药启动率.
- 为了确定与此群体中抗抑郁药使用相关的因素.
- 调查ICU幸存者的抗抑郁药使用和死亡率之间的联系.
主要方法:
- 在2010年至2017年期间,全国范围内对125,130名ICU幸存者进行了队列研究,这些幸存者在2010年至2017年期间入院.
- 分析退院后3个月和1年内开始服用抗抑郁药的情况.
- 在2年的随访期间识别相关因素和死亡结果.
主要成果:
- 7%的ICU幸存者在3个月内开始服用抗抑郁药,15.5%在1年内开始服用抗抑郁药,在2年内没有减少.
- 抗抑郁药的使用与中年,女性性别,并发症,物质依赖,更高的疾病严重程度和更长的重症监护室停留有关.
- 抗抑郁药使用者死亡率较高,因外部原因和自杀导致的死亡率增加.
结论:
- 显著比例的ICU幸存者开始服用抗抑郁药物,突出显示了ICU后抑郁症的流行.
- 特定的患者特征和ICU经验与抗抑郁药的使用有关.
- 在ICU幸存者中使用抗抑郁药与死亡率的增加有关,这强调了需要仔细监测和管理的必要性.
相关概念视频
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
358
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
358
01:25Antidepressant Drugs: Overview
430
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
430
01:23Antidepressant Drugs: MAOIs and Other Agents
215
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
215
01:30Electroconvulsive Therapy
31
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
31
01:28Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
01:26Psychosis: Goals of Pharmacotherapy
119
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
119